Clinical trial NCT01043016: Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors
Official title: Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Skin Cancer
Esophageal Cancer
Keywords: skin cancer
esophageal cancer
photodynamic therapy
Lead sponsor: Fujian Longhua Pharmaceutical Co. Ltd
Sponsor class: OTHER
Collaborators: name: Fuzhou University
name: Sun Yat-sen University
First posted: 2010-01-06
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and maximum tolerated dose of Photocyanine injection in photodynamic therapy of malignant tumor (especially skin cancer and esophageal cancer).

Projected accrual: A total of 18-24 patients will be accrued for this study.

Detailed description: Photocyanine injection is a type of cyanine compound, which was invented in Fuzhou university by Professor Chen; it's maximum absorption wave is 670 nm. Patients receive intravenous injection of Photocyanine injection, and 24 hours later, patients undergo photodynamic therapy.

Cohorts of 3-6 patients receive escalating doses of Photocyanine Injection and photodynamic therapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3 patients experiences dose-limiting toxicity. Three additional patients are treated at the MTD.

After completion of study therapy, patients are followed for up to 2 weeks.

Eligibility criteria: Inclusion Criteria:

1. Aged 18 to 70 years old (patient over 60 years old must not have three kinds of complications of heart, lung, liver and kidney function at the same time), no gender limited;
2. Advanced malignant solid tumors confirmed by histology or cytology ( skin cancer and esophageal cancer), malignant tumor can be illuminated directly (or via endoscopy) by the laser fiber;
3. Recurrence after surgery, radiotherapy,chemoradiotherapy; or have financial difficulties, give up any other treatment;
4. Patients received chemotherapy, biological therapy or other research drugs must exceed at least 4 weeks or more than five half-life;
5. Life expectancy: \> 3 months;
6. Can collaboratively observe the adverse events and efficacy;
7. No other anti-tumor treatment (including steroids);
8. Patients or their legal representative can sign the informed consent;
9. Performance status: ECOG ≤ 2,

Exclusion Criteria:

1. No pathological evidence;
2. Have allergic effect to this drug;
3. HIV antibody positive, or suffering from other acquired and congenital immune deficiency diseases, or have organ transplant history;
4. Neutrophil count \< 1.5 × 109 / L, platelet \< 100 × 109 / L, or hemoglobin \< 90 g /L;
5. Serum Cr above 1.5 times of normal reference range or Cr clearance rate \< 50 ml/min;
6. ALT, or AST \> 2.5 times of the normal range when no hepatic metastasis occur; or ALT, or AST \> 5 times of the normal range when hepatic metastasis exist;
7. Serum bilirubin \> 1.5 times of the normal range;
8. Fever above 38 ℃, or have active infection which can affect the clinical trials obviously;
9. Hypertension failed to be controlled (systolic blood pressure \> 160 mmHg or diastolic pressure \> 100 mmHg);
10. Obvious cardiovascular disorders (eg, myocardial infarction, superior vena cava syndrome, more than two grades heart disease, or heart disease which can increase the risk of ventricular arrhythm);
11. Not recover from any anticancer therapy or surgery;
12. Any clinical problems beyond control (such as severe mental, neurological, cardiovascular, respiratory system diseases, etc.);
13. Evidence of central nerve system metastasis;
14. Have some gastrointestinal disease which can affect the distribution, metabolism or removal of this drug;
15. Pregnant or breast-feeding women;
16. Poor compliance.

Primary outcomes:
measure: Maximum tolerated dose
timeFrame: one month
Secondary outcomes:
measure: Treatment efficacy as measured by computed tomography (CT) or magnetic resonance imaging (MRI) and endoscopy exam 3 weeks after the start of study treatment according to the Response Evaluation Criteria In Solid Tumors (RECIST) standard
timeFrame: six weeks
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of Endoscopy and Laser,Sun Yat-Sen University,Cancer Center
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: guo l xu
role: PRINCIPAL_INVESTIGATOR
References: